• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Press Releases 

Events & Mediawatch 

 June 4, 2025   Sweden

Events & Mediawatch 

 June 2, 2025   Sweden

Events & Mediawatch 

 May 8, 2025   Sweden

Events & Mediawatch 

 April 25, 2025   Sweden

Events & Mediawatch 

 April 24, 2025   Sweden

Company Presentation

 April 15, 2025
Download PDF

The progress we are making brings us closer to a transformative milestone: the expected early readout from our Phase 3 trial DIAGNODE-3 in one year’s time.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly report 2, 24/25

Calendar

 Dates for financial information and other events
June 17 − June 18, 2025
21st Century Trials in New-Onset T1D
June 20 − June 23, 2025
ADA 85th Scientific Sessions
June 25, 2025
Quarterly Report 3
Quarterly Report 3 2024/2025
June 25, 2025
Diamyd Medical - Kvartalsuppdatering
September 15 − September 19, 2025
EASD 61st Annual meeting
October 8, 2025
Year-end Report
Year-end Report 2024/2025

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

Image
A facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden.
Read More

THE COMPANY

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  December 3, 2024
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research